Michael Aberman, M.D. is president and chief executive officer of Quentis Therapeutics. Prior to joining Quentis, Dr. Aberman spent over seven years at Regeneron Pharmaceuticals as the Senior Vice President of Investor Relations and Strategy. In that role, Dr. Aberman was a member of the senior management team and was responsible for the investor relations, corporate communications, business development, and corporate strategy functions at Regeneron.

Prior to joining Regeneron, Dr. Aberman spent six years as a Wall Street research analyst covering the biotechnology industry at Credit Suisse and Morgan Stanley. Before moving to Wall Street, Dr. Aberman was Director of Business Development at Antigenics, Inc., an oncology-focused biotechnology company. Dr. Aberman received his B.A. from Cornell University and his medical degree from the University of Toronto. He completed his residency training at New York Presbyterian Hospital and received an M.B.A. from The Wharton School of Business.

David Erickson is the Associate Dean of Engineering for Research and Graduate Programs, the Sibley College Professor in the Sibley School of Mechanical and Aerospace Engineering, and joint Professor within the Division of Nutritional Sciences at Cornell University. His research focuses on: mobile and global health technology, medical diagnostics, microfluidics, photonics, and nanotechnology.

Prior to joining the faculty, he was a
postdoctoral scholar at the California Institute of Technology and he received his Ph.D. degree from the University of Toronto. Research in the Erickson lab is primarily funded through grants from the NSF, NIH, ARPA-E, ONR,
DOE, DOD, Nutrition International, and Global Alliance for Improved Nutrition (GAIN).

Prof. Erickson has helped to found numerous start-up companies commercializing: high-throughput pharmaceutical instrumentation,
biomedical diagnostics, and energy technologies including Halo Labs (http://halolabs.com), VitaScan
(http://vitascan.me) and Dimensional Energy (https://www.dimensionalenergy.net/).

Dr. Erickson has received the DARPA-MTO Young Faculty Award, the NSF CAREER Award, the Department of Energy Early Career Award,
among others.

In 2011 he was awarded the Presidential Early Career Award for Scientist and Engineers (PECASE) by President Obama. For his efforts in co-founding the field of optofluidics, Erickson has been named a fellow of the Optical Society of America and the American Society of Mechanical Engineers.

Nancy joined Kallyope as Chief Executive Officer at the company’s launch in November 2016. She was formerly Senior Vice President and Franchise Head, Diabetes and Endocrinology, Merck & Co. Inc. In this role she led discovery and clinical research in diabetes, osteoporosis, fertility and contraception. Prior to her role as Franchise Head, Nancy initiated and was a leader of Merck’s dipeptidyl peptidase 4 (DPP-4) project, which resulted in the discovery of JANUVIA® for the treatment of Type 2 diabetes. Among other notable scientific accomplishments is the identification of the first caspase, interleukin-1β converting enzyme (ICE/caspase-1).

For her scientific contributions she has received numerous awards, including the Merck Presidential Fellowship, Merck Directors Award, Heroes of Chemistry Award by the American Chemical Society, and in 2011 received the Pharmaceuticals Research and Manufacturers of America (PhRMA) Discoverers Award, which honors research scientists whose work has been of special benefit to humankind. In addition to her role at Kallyope, she serves as a Director at Intarcia Therapeutics and Abide Therapeutics.